Safety and efficacy of bendamustine plus melphalan conditioning regimen followed by autologous stem cell transplantation in patients with multiple myeloma.

Trial Profile

Safety and efficacy of bendamustine plus melphalan conditioning regimen followed by autologous stem cell transplantation in patients with multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Bendamustine (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2017 New trial record
    • 12 Dec 2017 Results assessing efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top